{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:12:41Z","timestamp":1788361961424,"version":"build-2803163510"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19ck0106350h0003"],"award-info":[{"award-number":["19ck0106350h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Center Research and Development Fund","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer originating in the biliary tract can be classified as bile duct cancer (cholangiocarcinoma), gallbladder cancer, or ampullary cancer. Bile duct cancer is further divided to intrahepatic, perihilar and distal bile duct subtypes according to the anatomical location of the tumor. The biological characteristics of each tumor are heterogeneous. However, because of the rarity of each disease, the efficacy of new drugs has been tested in groups of patients with different biliary tract cancers. In patients with metastatic or recurrent biliary tract cancer, recent randomized clinical trials revealed the non-inferiority of gemcitabine + S-1 and the superiority of gemcitabine + cisplatin + S-1 compared with gemcitabine + cisplatin in terms of overall survival, thereby establishing a new standard treatment. In the field of adjuvant therapy for biliary tract cancer, the British BILCAP (capecitabine compared with observation in resected biliary tract cancer) study revealed longer median overall survival in the capecitabine group than in the observation group in the per-protocol analysis (but not in the intention-to-treat analysis), bringing a shift toward postoperative management. Several other studies of adjuvant therapy are ongoing, and they may lead to reforms in treatment strategy for resectable biliary tract cancer in the future. The use of neoadjuvant therapy for biliary tract cancer is in its infancy, but it is expected to overcome the limitations of adjuvant therapy for this malignancy. In this review, we summarized the evidence available from clinical trials of adjuvant and neoadjuvant therapy for biliary tract cancer and described ongoing clinical trials.<\/jats:p>","DOI":"10.1093\/jjco\/hyaa170","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T12:13:34Z","timestamp":1598012014000},"page":"1353-1363","source":"Crossref","is-referenced-by-count":34,"title":["Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3516-8765","authenticated-orcid":false,"given":"Satoshi","family":"Nara","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Esaki","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ban","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Takamoto","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0197-1832","authenticated-orcid":false,"given":"Tatsuya","family":"Ioka","sequence":"additional","affiliation":[{"name":"Oncology Center, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami Kogushi Ube-shi, Yamaguchi, 755-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba, 260-8717, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kyorin University Faculty of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"2020121604540555500_ref1","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017","edition":"8th"},{"key":"2020121604540555500_ref2","volume-title":"TNM Classifacation of Malignat Tumours","author":"Brierley","year":"2017","edition":"8th"},{"key":"2020121604540555500_ref3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2020121604540555500_ref4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2015.12.012","article-title":"Genomic sequencing identifies ELF3 as a driver of Ampullary carcinoma","volume":"29","author":"Yachida","year":"2016","journal-title":"Cancer Cell"},{"key":"2020121604540555500_ref5","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.2015.61.6953","article-title":"Biliary tract cancers: finding better ways to lump and split","volume":"33","author":"Kelley","year":"2015","journal-title":"J Clin Oncol"},{"key":"2020121604540555500_ref6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2020121604540555500_ref7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"key":"2020121604540555500_ref8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"2020121604540555500_ref9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and Oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020121604540555500_ref10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"2020121604540555500_ref11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/jjco\/hyy004","article-title":"A randomized phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan clinical oncology Group study (JCOG1202, ASCOT)","volume":"48","author":"Nakachi","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"2020121604540555500_ref12","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"2020121604540555500_ref13","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy282","article-title":"615ORandomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)","volume":"29","author":"Sakai","year":"2018","journal-title":"Ann Oncol"},{"key":"2020121604540555500_ref14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jhbp.314","article-title":"Biliary tract cancer registry in Japan from 2008 to 2013","volume":"23","author":"Ishihara","year":"2016","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2020121604540555500_ref15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cncr.29686","article-title":"Proposal of a new staging system for intrahepatic cholangiocarcinoma: analysis of surgical patients from a nationwide survey of the liver cancer study Group of Japan","volume":"122","author":"Sakamoto","year":"2016","journal-title":"Cancer"},{"key":"2020121604540555500_ref16","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/cncr.11699","article-title":"Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies","volume":"98","author":"Jarnagin","year":"2003","journal-title":"Cancer"},{"key":"2020121604540555500_ref17"},{"key":"2020121604540555500_ref18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"2020121604540555500_ref19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00280-014-2543-4","article-title":"Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study","volume":"74","author":"Kobayashi","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"2020121604540555500_ref20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00280-014-2431-y","article-title":"Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004)","volume":"73","author":"Toyoda","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"2020121604540555500_ref21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00280-017-3513-4","article-title":"A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202)","volume":"81","author":"Yanagimoto","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2020121604540555500_ref22","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00280-011-1805-7","article-title":"A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures","volume":"69","author":"Takahara","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"2020121604540555500_ref23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143072","article-title":"Pharmacokinetic study of adjuvant gemcitabine therapy for biliary tract cancer following major hepatectomy (KHBO1101)","volume":"10","author":"Fujiwara","year":"2015","journal-title":"PLoS One"},{"key":"2020121604540555500_ref24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/jhbp.283","article-title":"Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer","volume":"22","author":"Kainuma","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2020121604540555500_ref25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12885-017-3967-0","article-title":"Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase II study","volume":"18","author":"Siebenhuner","year":"2018","journal-title":"BMC Cancer"},{"key":"2020121604540555500_ref26","volume-title":"Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma"},{"key":"2020121604540555500_ref27","volume-title":"Randomized Phase II study of adjuvant chemotherapy with gemcitabine plus cisplatin versus gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy(KHBO1901)"},{"key":"2020121604540555500_ref28","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: a phase II intergroup trial of adjuvant Capecitabine and gemcitabine followed by radiotherapy and concurrent Capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"key":"2020121604540555500_ref29","volume-title":"Adjuvant Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer (ACCORD)"},{"key":"2020121604540555500_ref30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/SLA.0000000000002865","article-title":"A prospective, randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-biliary oncology Group","volume":"270","author":"Kobayashi","year":"2019","journal-title":"Ann Surg"},{"key":"2020121604540555500_ref31","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-020-08355-3","article-title":"Phase 2 trial of adjuvant chemotherapy with S - 1 for node-positive biliary tract cancer (N-SOG 09)","author":"Seita","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2020121604540555500_ref32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"2020121604540555500_ref33","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.10831","article-title":"Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma","volume":"95","author":"Takada","year":"2002","journal-title":"Cancer"},{"key":"2020121604540555500_ref34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","article-title":"Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial","volume":"15","author":"Stein","year":"2015","journal-title":"BMC Cancer"},{"key":"2020121604540555500_ref35","volume-title":"Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma"},{"key":"2020121604540555500_ref36","volume-title":"Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection (AdBTC-1)"},{"key":"2020121604540555500_ref37","first-page":"1866","article-title":"Phase I trial of neoadjuvant chemoradiation with gemcitabine and surgical resection for cholangiocarcinoma patients (NACRAC study)","volume":"58","author":"Katayose","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"2020121604540555500_ref38","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-015-2908-3","article-title":"Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer","volume":"76","author":"Kobayashi","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2020121604540555500_ref39","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/SLA.0b013e31829b3ce4","article-title":"Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer","volume":"258","author":"Takahashi","year":"2013","journal-title":"Ann Surg"},{"key":"2020121604540555500_ref40","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1002\/cncr.11401","article-title":"Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study","volume":"97","author":"Wiedmann","year":"2003","journal-title":"Cancer"},{"key":"2020121604540555500_ref41","doi-asserted-by":"crossref","first-page":"26619","DOI":"10.3390\/ijms161125978","article-title":"Neoadjuvant down-sizing of hilar cholangiocarcinoma with photodynamic therapy\u2013long-term outcome of a phase II pilot study","volume":"16","author":"Wagner","year":"2015","journal-title":"Int J Mol Sci"},{"key":"2020121604540555500_ref42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1200\/jco.2015.33.3_suppl.402","article-title":"Neoadjuvant chemoradiation therapy for cholangiocarcinoma to improve R0 resection rate: the first report of phase II study","volume":"33","author":"Katayose","year":"2015","journal-title":"J Clin Oncol"},{"key":"2020121604540555500_ref43","volume-title":"A multicenter phase II trial of pre-operative chemotherapy with Gemcitabine\/Cisplatin\/S-1 for biliary tract cancers with lymph node metastasis diagnosed by FDG-PET"},{"key":"2020121604540555500_ref44","volume-title":"Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer (DEBATE)"},{"key":"2020121604540555500_ref45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12885-020-6610-4","article-title":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC\/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO\/CALGP\/ACO-GAIN-trial","volume":"20","author":"Goetze","year":"2020","journal-title":"BMC Cancer"},{"key":"2020121604540555500_ref46","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020121604540555500_ref47","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers Version 1. 2020","author":"NCCN","year":"2020"},{"key":"2020121604540555500_ref48","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1470-2045(19)30022-1","article-title":"Adjuvant capecitabine in biliary tract cancer: a standard option?","volume":"20","author":"Malka","year":"2019","journal-title":"Lancet Oncol"},{"key":"2020121604540555500_ref49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00534-011-0498-y","article-title":"Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors","volume":"19","author":"Murakami","year":"2012","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2020121604540555500_ref50","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/SLA.0b013e3181b0fc8b","article-title":"Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma","volume":"250","author":"Murakami","year":"2009","journal-title":"Ann Surg"},{"key":"2020121604540555500_ref51","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1245\/s10434-010-1325-4","article-title":"Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma","volume":"18","author":"Murakami","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"2020121604540555500_ref52","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1007\/s11605-009-0900-0","article-title":"Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma","volume":"13","author":"Murakami","year":"2009","journal-title":"J Gastrointest Surg"},{"key":"2020121604540555500_ref53","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4236\/jct.2011.25095","article-title":"Comparison of 4-weekly vs 3-weekly gemcitabine as adjuvant chemotherapy following curative resection for biliary tract cancer: a prospective randomized controlled trial","volume":"02","author":"Kobayashi","year":"2011","journal-title":"J Cancer Ther"},{"key":"2020121604540555500_ref54","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10147-013-0578-x","article-title":"A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer","volume":"19","author":"Yamanaka","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"2020121604540555500_ref55","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"2020121604540555500_ref56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jhbp.344","article-title":"Validation of the board certification system for expert surgeons (hepato-biliary-pancreatic field) using the data of the National Clinical Database of Japan: part 1 - hepatectomy of more than one segment","volume":"23","author":"Miura","year":"2016","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2020121604540555500_ref57","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jhbp.348","article-title":"Validation of the board certification system for expert surgeons (hepato-biliary-pancreatic field) using the data of the National Clinical Database of Japan: part 2 - Pancreatoduodenectomy","volume":"23","author":"Miura","year":"2016","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2020121604540555500_ref58","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jhbp.444","article-title":"Safety-related outcomes of the Japanese Society of Hepato-Biliary-Pancreatic Surgery board certification system for expert surgeons","volume":"24","author":"Otsubo","year":"2017","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2020121604540555500_ref59","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/SLA.0000000000000263","article-title":"A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy","volume":"259","author":"Kimura","year":"2014","journal-title":"Ann Surg"},{"key":"2020121604540555500_ref60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/SLA.0b013e3182708b57","article-title":"Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections","volume":"258","author":"Nagino","year":"2013","journal-title":"Ann Surg"},{"key":"2020121604540555500_ref61","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J Clin Oncol"},{"key":"2020121604540555500_ref62","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00595-016-1362-0","article-title":"The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival","volume":"47","author":"Wellner","year":"2017","journal-title":"Surg Today"},{"key":"2020121604540555500_ref63","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.2019.37.4_suppl.189","article-title":"Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP-05)","volume":"37","author":"Unno","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020121604540555500_ref64","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9041129","article-title":"Neoadjuvant therapy for Resectable and borderline Resectable pancreatic cancer: a meta-analysis of randomized controlled trials","volume":"9","author":"Cloyd","year":"2020","journal-title":"J Clin Med"},{"key":"2020121604540555500_ref65","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"2020121604540555500_ref66","article-title":"New and emerging systemic therapeutic options for advanced cholangiocarcinoma","volume":"9","author":"Massironi","year":"2020","journal-title":"Cell"},{"key":"2020121604540555500_ref67","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/hep.27944","article-title":"Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma","volume":"63","author":"Yang","year":"2016","journal-title":"Hepatology"},{"key":"2020121604540555500_ref68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00324","article-title":"Circulating tumor DNA profiling of advanced biliary tract cancers","author":"Mody","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"2020121604540555500_ref69","first-page":"99","article-title":"Adjuvant chemotherapy with gemcitabine for resected biliary tract cancer : a single-arm phase 2 study","volume":"65","author":"Kitagawa","year":"2017","journal-title":"Shinshu Medical Journal"},{"key":"2020121604540555500_ref70","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s10147-018-1283-6","article-title":"Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer","volume":"23","author":"Nakachi","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"2020121604540555500_ref71","volume-title":"Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1)"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/12\/1353\/34925273\/hyaa170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/12\/1353\/34925273\/hyaa170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T08:26:45Z","timestamp":1723451205000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/50\/12\/1353\/5919787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":71,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,10,10]]},"published-print":{"date-parts":[[2020,12,16]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa170","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,10,10]]}}}